3 Stock Stars Yielding Around 5% In 2015: GlaxoSmithKline plc, Legal & General Group Plc & Old Mutual plc

Royston Wild explains why GlaxoSmithKline plc (LON: GSK), Legal & General Group Plc (LON: LGEN) and Old Mutual plc (LON: OML) should attract savvy dividend seekers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three blue-chip winners set to deliver stunning returns in 2015.

GlaxoSmithKline

The effect of revenues-sapping patent losses has weighed heavily on GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) bottom line in recent years, and the firm has failed to punch two consecutive years of growth for what seems an age now. And City analysts expect this trend to continue during the medium term at least, with a 17% earnings slide pencilled in for this year.

Despite these travails, the pharma giant’s ability to throw up plenty of cash has enabled it to continue raising the full-year dividend during this time — GlaxoSmithKline has lifted the payment at a compound annual growth rate of 6.3% during the past five years alone.

And the number crunchers expect the dividends to continue rolling higher as a result, and GlaxoSmithKline is anticipated to raise the payout 3% in 2014, to 80.1p per share, and a further 1% next year to 81p. Consequently the Brentford firm boasts a chunky yield of 5.4% for this year — comfortably above the 3.3% FTSE 100 average — and which advances to 5.5% for 2015.

Earnings are expected to flip 1% higher next year as the company’s promising drug pipeline begins to deliver the next generation of sales-boosting drugs, a promising omen for future payout growth. And with GlaxoSmithKline embarking on a new £1bn cost-saving initiative, I believe that the firm’s already-attractive dividend outlook should improve considerably in coming years.

Legal & General Group

Backed up by an aggressive acquisition policy and emphasis on developing its brand in emerging markets, Legal & General (LSE: LGEN) (NASDAQOTH: LGGNY.US) has seen growth spurt skywards during the past couple years. When combined with the firm’s terrific cash-generative qualities, boosted by surging business inflows, dividends are expected to keep marching higher though to the end of 2015.

Indeed, an 11% earnings advance in 2014 is anticipated to push the full-year dividend 19% higher this year to 11.1p per share. And an additional 9% increase in 2015 will drive the payout 13% northwards to 12.5p, according to City analysts. As a result Legal & General’s chunky yield of 4.5% for this year shoots to a wallet-busting 5.1% for 2015.

Legal & General has seen the value of its international assets treble during the past four years, and I believe that a backcloth of rising affluence levels and low product penetration in key growth markets should keep the sales column ticking higher. Meanwhile a diversified product base spanning the insurance, savings and investment spheres should guard against earnings weakness and keep dividends flowing.

Old Mutual

Life insurance giant Old Mutual (LSE: OML) has maintained an ultra-progressive dividend policy in recent years despite the effect of wavering earnings growth, a phenomenon which the abacus bashers expect to continue during the next 12 months at least.

A 9% advance in the full-year payout is currently pencilled in for 2014, to 8.75p per share, despite an anticipated 10% earnings drop. And with the bottom line predicted to expand 16% in 2015, Old Mutual will push the dividend 13% higher to 9.9p, according to current forecasts.

Accordingly, yields at the business rise from 4.3% this year to a far more appetising 4.9% for 2015.

The firm’s huge reliance on the South African market has seen group sales slow more recently owing to weak consumer trends there. Still, I believe that once current cyclical woes in its critical African markets abate — boosted by improvements in its product distribution infrastructure — Old Mutual should see earnings and dividends continue to surge beyond next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

10% dividend growth! 2 FTSE 100 stocks tipped to supercharge cash payouts

These FTSE 100 stocks have strong records of dividend growth. And they're expected to keep on delivering, as Royston Wild…

Read more »

Investing Articles

Down 17% in a month and yielding 7.39%! Is this FTSE 100 share a screaming buy for me?

When Harvey Jones bought Taylor Wimpey last year he thought this FTSE 100 share was a brilliant long-term buy-and-hold. Has…

Read more »

Investing Articles

Here’s how I’m using a £20k ISA to target £11k+ in income 30 years from now

Is it realistic to put £20k in an ISA now and earn over half that amount every year in passive…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

If I could only keep 5 UK stocks from my portfolio I’d save these

Harvey Jones is running through his portfolio of top UK stocks to see which ones he couldn't bear to do…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

I’m aiming for a million buying unexciting shares!

By investing regularly in long-established, proven and even rather dull businesses, this writer plans to aim for a million. Here's…

Read more »

Investing Articles

3 things to consider before you start investing

Our writer draws on his stock market experience to consider a few vital lessons he would use to start investing…

Read more »

Investing Articles

Will this lesser-known £28bn growth stock be joining the FTSE 100 soon?

As the powers that be plan a reorganisation of Footsie listing rules, this massive under-the-radar growth stock could find its…

Read more »

Investing Articles

Fools wouldn’t touch these 5 FTSE 350 flops with a bargepole – how come I own 3 of them?

Harvey Jones took a chance on three struggling FTSE 350 stocks in the hope that they'd stage a dramatic recovery.…

Read more »